A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Description

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).

Conditions

Dermatitis Atopic

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Condition
Dermatitis Atopic
Intervention / Treatment

-

Contacts and Locations

Scottsdale

Center for Dermatology and Plastic Surgery- Site Number : 8401119, Scottsdale, Arizona, United States, 85260

Little Rock

Arkansas Dermatology- Site Number : 8401244, Little Rock, Arkansas, United States, 72117

Encino

Encino Research Center- Site Number : 8401042, Encino, California, United States, 91436

Fremont

Center for Dermatology Clinical Research- Site Number : 8401018, Fremont, California, United States, 94538

Long Beach

Long Beach Clinical Trials- Site Number : 8401188, Long Beach, California, United States, 90806

Los Angeles

Dermatology Research Associates - Los Angeles- Site Number : 8401092, Los Angeles, California, United States, 90045

Los Angeles

LA Universal Research Center- Site Number : 8401064, Los Angeles, California, United States, 90057

Wheat Ridge

Paradigm Research - Wheat Ridge- Site Number : 8401245, Wheat Ridge, Colorado, United States, 80033

Boynton Beach

Encore Medical Research of Boynton Beach LLC. - Site Number : 8401030, Boynton Beach, Florida, United States, 33021

Saint Petersburg

Global Clinical Professionals (GCP)- Site Number : 8401045, Saint Petersburg, Florida, United States, 33705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants must be 12 years of age (when signing informed consent form)
  • * Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)
  • * Documented history prior to screening visit of inadequate response to a biologic AD medication or an oral JAKi therapy.
  • * v-IGA-AD of 3 or 4 at baseline visit
  • * EASI score of 16 or higher at baseline
  • * AD involvement of 10% or more of BSA at baseline
  • * Weekly average of daily PP-NRS of ≥ 4 at baseline visit.
  • * Able and willing to comply with requested study visits and procedures
  • * Body weight ≥25 kg
  • * Skin co-morbidity that would adversely affect the ability to undertake AD assessments
  • * Known history of or suspected significant current immunosuppression
  • * Any malignancies or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured \>5 years prior to baseline)
  • * History of solid organ or stem cell transplant
  • * Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline
  • * Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit
  • * Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
  • * Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
  • * In the Investigator's opinion, any clinically significant laboratory results or protocol specified laboratory abnormalities at screening
  • * History of hypersensitivity or allergy to any of the excipients or investigational medicinal product (IMP)

Ages Eligible for Study

12 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sanofi,

Study Record Dates

2026-06-30